Inventor · disambiguated record
David Paul Humphreys
Also filed as: HUMPHREYS DAVID P · HUMPHREYS DAVID PAUL
45 granted patents·15 pending applications·299 citations·filing 1998–2022
98Inventor score
Top patents by PatentIndex Score
60 records- 0195US9315770B2Bacterial host strainUCB PHARMA SA·Filed 2015·Granted Apr 19, 2016·11 cites·20 claims
- 0294US9873735B2Method of treatment with antibodies having specificity for human OX40UCB BIOPHARMA SPRL·Filed 2015·Granted Jan 23, 2018·12 cites·50 claims
- 0394US9309327B2Dual specificity antibody fusionsUCB PHARMA SA·Filed 2013·Granted Apr 12, 2016·32 cites·7 claims
- 0494US9040048B2Antibody molecules having specificity for human OX40UCB PHARMA SA·Filed 2012·Granted May 26, 2015·19 cites·11 claims
- 0593US11059911B2Sequence symmetric modified IgG4 bispecific antibodiesUCB BIOPHARMA SPRL·Filed 2019·Granted Jul 13, 2021·8 cites·19 claims
- 0693US9109216B2Bacterial host strainELLIS MARK·Filed 2010·Granted Aug 18, 2015·14 cites·42 claims
- 0792US9493558B2Bacterial host strain comprising a mutant SPR gene and a wild-type TSP geneUCB PHARMA SA·Filed 2015·Granted Nov 15, 2016·5 cites·24 claims
- 0892US8969038B2Bacterial host strain expressing recombinant DsbC and having reduced Tsp activityELLIS MARK·Filed 2011·Granted Mar 3, 2015·14 cites·22 claims
- 0991US10221251B2Sequence symmetric modified IGG4 bispecific antibodiesUCB BIOPHARMA SPRL·Filed 2013·Granted Mar 5, 2019·11 cites·36 claims
- 1091US9550973B2Bacterial host strainUCB PHARMA SA·Filed 2016·Granted Jan 24, 2017·5 cites·25 claims
- 1191US8969037B2Bacterial host strain comprising a mutant spr gene and a wild-type Tsp geneELLIS MARK·Filed 2011·Granted Mar 3, 2015·12 cites·21 claims
- 1291US8969039B2Bacterial host strain comprising a mutant SPR gene and having reduced TSP activityELLIS MARK·Filed 2011·Granted Mar 3, 2015·14 cites·27 claims
- 1391US8629246B2Dual specificity antibody fusionsHUMPHREYS DAVID PAUL·Filed 2008·Granted Jan 14, 2014·21 cites·8 claims
- 1491US8507654B2Altered antibodiesBAKER TERENCE S·Filed 2007·Granted Aug 13, 2013·14 cites·9 claims
- 1589US9828438B2Dual specificity antibody fusionsUCB PHARMA SA·Filed 2016·Granted Nov 28, 2017·7 cites·8 claims
- 1689US9493559B2Bacterial host strain expressing recombinant DsbC and having reduced Tsp activityUCB PHARMA SA·Filed 2015·Granted Nov 15, 2016·5 cites·26 claims
- 1789US8053562B2Modified antibody fragmentsUCB PHARMA SA·Filed 2006·Granted Nov 8, 2011·13 cites·12 claims
- 1888US9803004B2Albumin binding antibodies and binding fragments thereofUCB BIOPHARMA SPRL·Filed 2012·Granted Oct 31, 2017·10 cites·11 claims
- 1987US10100130B2Dual specificity antibody fusionsUCB PHARMA SA·Filed 2017·Granted Oct 16, 2018·5 cites·11 claims
- 2083US9587227B2Bacterial host strain comprising a mutant spr gene and having reduced Tsp activityUCB PHARMA SA·Filed 2015·Granted Mar 7, 2017·2 cites·34 claims
- 2182US10421816B2Multivalent antibodiesUCB PHARMA SA·Filed 2016·Granted Sep 24, 2019·2 cites·9 claims
- 2282US10023631B2Albumin binding antibodies and binding fragments thereofUCB BIOPHARMA SPRL·Filed 2017·Granted Jul 17, 2018·3 cites·3 claims
- 2382US9725516B2Bacterial host strain expressing recombinant DSBCELLIS MARK·Filed 2012·Granted Aug 8, 2017·3 cites·20 claims
- 2481US9957328B2Bacterial host strain expressing recombinant DSBCUCB PHARMA SA·Filed 2017·Granted May 1, 2018·1 cites·27 claims
- 2581US9951365B2Recombinant bacterial host cell for protein expressionUCB PHARMA SA·Filed 2013·Granted Apr 24, 2018·4 cites·21 claims
- 2680US9902768B2Sequence asymmetric modified IgG4 bispecific antibodiesUCB PHARMA SA·Filed 2013·Granted Feb 27, 2018·5 cites·37 claims
- 2779US9045529B2Disulfide stabilized antibodies and fragments thereofHUMPHREYS DAVID PAUL·Filed 2011·Granted Jun 2, 2015·2 cites·13 claims
- 2877US10562966B2Antibodies of the class IGG4HUMPHREYS DAVID PAUL·Filed 2011·Granted Feb 18, 2020·4 cites·19 claims
- 2977US10457748B2Single linker FabFv antibodies and methods of producing sameUCB BIOPHARMA SPRL·Filed 2013·Granted Oct 29, 2019·3 cites·24 claims
- 3077US6642356B1Peptides which function as hinge regions in proteinCELLTECH THERAPEUTICS LTD·Filed 1998·Granted Nov 4, 2003·28 cites·10 claims
- 3174US11261470B2Recombinant bacterial host cell for protein expressionUCB Biopharma SRL·Filed 2018·Granted Mar 1, 2022·1 cites·20 claims
- 3273US12428497B2Multispecific antibody constructsUCB Biopharma SRL·Filed 2022·Granted Sep 30, 2025·0 cites·23 claims
- 3373US8062865B2Expression control using antibody expression optimisation sequencesHUMPHREYS DAVID PAUL·Filed 2006·Granted Nov 22, 2011·1 cites·6 claims
- 3472US7989594B2Modified antibody fab fragmentsUCB PHARMA SA·Filed 2004·Granted Aug 2, 2011·5 cites·16 claims
- 3571US11345760B2Multispecific antibody constructsUCB Biopharma SRL·Filed 2015·Granted May 31, 2022·1 cites·26 claims
- 3670US7662609B2E.coli host cells with modified PhoS/PstS periplasmic phosphate-binding proteins, and method of manufacturing recombinant fabsUCB PHARMA SA·Filed 2003·Granted Feb 16, 2010·1 cites·7 claims
- 3769US12091450B2Antibodies of the class IGG4UCB PHARMA SA·Filed 2019·Granted Sep 17, 2024·0 cites·6 claims
- 3867US11427650B2Dual specificity antibody fusionsUCB PHARMA SA·Filed 2019·Granted Aug 30, 2022·0 cites·12 claims
- 3967US10472426B2Disulfide stabilized DVD-Ig moleculesHEYWOOD SAM PHILIP·Filed 2011·Granted Nov 12, 2019·1 cites·6 claims
- 4061US2010285530A1E.Coli Host Cells with Modified Phos/Psts Periplasmic Phosphate-binding Proteins, and Method of Manufacturing Recombinant FabsUCB PHARMA SA·Filed 2009·Application pending·0 cites
- 4159US2023374148A1Binding molecules that multimerise cd45UCB Biopharma SRL·Filed 2021·Application pending·0 cites
- 4256US2025026836A1Anti-hla-g antibodiesUCB Biopharma SRL·Filed 2022·Application pending·0 cites
- 4355US11401349B2Single linker FabFv antibodies and methods of producing sameUCB BIOPHARMA SPRL·Filed 2019·Granted Aug 2, 2022·0 cites·28 claims
- 4454US2007059301A1Modified antibody fragmentsCILLTECH R & D LTD·Filed 2004·Application pending·0 cites
- 4553US2020377578A1Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficileUCB BIOPHARMA SPRL·Filed 2020·Application pending·0 cites
- 4651US10759844B2Disulfide stabilised antibodies and fragments thereofUCB PHARMA SA·Filed 2015·Granted Sep 1, 2020·0 cites·6 claims
- 4751US10752676B2Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficileHUMPHREYS DAVID PAUL·Filed 2012·Granted Aug 25, 2020·0 cites·43 claims
- 4849US11091542B2Antibody molecules which bind TNF alphaUCB Biopharma SRL·Filed 2016·Granted Aug 17, 2021·0 cites·22 claims
- 4949US7244587B2Expression vectors encoding bacteriophage signal peptidesCELLTECH R&D LTD·Filed 2002·Granted Jul 17, 2007·0 cites·15 claims
- 5047US2007014802A1Modified antibody fragmentsCELLTECH R&D LTD·Filed 2004·Application pending·0 cites
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David Paul Humphreys files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →